102 related articles for article (PubMed ID: 24281238)
1. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
Hamaya E; Sowa H
Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238
[No Abstract] [Full Text] [Related]
2. In reply.
Urushihara H
Menopause; 2014 Jan; 21(1):110. PubMed ID: 24326283
[No Abstract] [Full Text] [Related]
3. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
Urushihara H; Kikuchi N; Yamada M; Yoshiki F; Miyauchi A
Menopause; 2009; 16(5):971-7. PubMed ID: 19357545
[TBL] [Abstract][Full Text] [Related]
5. Hypocalcemia induced by raloxifene.
Vu TD; Varadarajan S; Seeman E; Jerums G; MacIsaac RJ
Curr Drug Saf; 2012 Apr; 7(2):176-8. PubMed ID: 22873502
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
Ohta H; Hamaya E; Taketsuna M; Sowa H
Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
[TBL] [Abstract][Full Text] [Related]
7. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus in women can be RUTHless: lessons from the Raloxifene Use for The Heart (RUTH) Trial.
Budoff MJ
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):137-8. PubMed ID: 23481520
[No Abstract] [Full Text] [Related]
9. A postmenopausal woman developed a giant endometrial polyp during Raloxifene treatment.
Kutuk MS; Goksedef BP
J Obstet Gynaecol; 2011 Oct; 31(7):672. PubMed ID: 21973134
[No Abstract] [Full Text] [Related]
10. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
11. Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
Gorai I; Tanaka Y; Hattori S; Iwaoki Y
J Bone Miner Metab; 2010 Mar; 28(2):176-84. PubMed ID: 19657590
[TBL] [Abstract][Full Text] [Related]
12. Carotid artery intima-media thickness after raloxifene treatment.
Mack WJ; Dhungana B; Dowsett SA; Keech CA; Feng M; Li Y; Hodis HN
J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
Yoh K; Hamaya E; Urushihara H; Iikuni N; Yamamoto T; Taketsuna M; Miyauchi A; Sowa H; Tanaka K
Curr Med Res Opin; 2012 Nov; 28(11):1757-66. PubMed ID: 23035693
[TBL] [Abstract][Full Text] [Related]
14. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
15. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
Chmel R; Rob L; Strnad P
Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene vs tamoxifen.
Goldstein SR
JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
[No Abstract] [Full Text] [Related]
19. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
